Location History:
- Mundelein, IL (2013)
- Mundelein, IL (US) (2016 - 2022)
Company Filing History:
2 out of 822 
1 out of 3 
1 out of 832,843 Years Active: 2013-2022
Title: Wei Liu - Innovator in HCV Treatment
Introduction
Wei Liu is a notable inventor based in Mundelein, IL (US), recognized for his contributions to the field of antiviral therapies. He holds a total of 4 patents, focusing primarily on innovative methods for treating Hepatitis C virus (HCV) infections. His work has significantly advanced the development of interferon-free treatment options.
Latest Patents
Wei Liu's latest patents include groundbreaking methods for treating HCV. These inventions feature interferon-free therapies that aim to shorten the duration of treatment to no more than 12 weeks. The treatment involves administering at least two direct acting antiviral agents to a subject with HCV infection, without the use of interferon or ribavirin. Specifically, the treatment comprises (a) Compound 1 or a pharmaceutically acceptable salt thereof and (b) Compound 2 or a pharmaceutically acceptable salt thereof.
Career Highlights
Throughout his career, Wei Liu has worked with prominent companies in the pharmaceutical industry, including AbbVie Inc. and Abbott Research B.V. His experience in these organizations has contributed to his expertise in developing effective antiviral therapies.
Collaborations
Wei Liu has collaborated with several professionals in his field, including Sandeep Dutta and John Powell. These collaborations have fostered innovation and enhanced the development of his patented treatments.
Conclusion
Wei Liu's contributions to the treatment of HCV through his innovative patents highlight his significant role in advancing antiviral therapies. His work continues to impact the medical field positively, offering new hope for patients with HCV infections.